'EP0089' Trials Expanding to US and Europe After Korea and Australia
Shares of Genome & Company (314130.KQ) surged as clinical trials for 'EP0089,' an immuno-oncology drug candidate licensed to UK partner Ellipses Pharma, gained momentum.
According to the Korea Exchange on Wednesday, Genome & Company shares traded at 7,720 won, up 1,370 won, or 21.57%, from the previous session's close. The rally followed news that Genome & Company had completed the supply of active pharmaceutical ingredients for EP0089 clinical trials to Ellipses Pharma. Genome & Company signed a technology transfer agreement with Ellipses Pharma for EP0089 in February last year.
The supply completion is interpreted as a signal that Ellipses Pharma is fully launching EP0089 clinical trials. Ellipses Pharma is currently preparing to administer Phase 1/2a trials of EP0089 in patients with solid tumors in Korea and Australia. The trials will be expanded to the United States and Europe, recruiting a total of approximately 190 patients.
"The completion of this active pharmaceutical ingredient supply demonstrates that our collaboration with Ellipses Pharma is progressing smoothly as planned," said Hong Yu-suk, CEO of Genome & Company. "We expect the smooth clinical development of EP0089 to confirm its potential as a first-in-class immuno-oncology drug."
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Min Byoung-kwon (Commentary)
Seoul Economic Daily (Commentary)
Seoul Economic Daily (Commentary)
Seoul Economic Daily (Commentary)
SEDaily Editorial Board (Opinion)
Copyright ⓒ Sedaily, All right reserved